Swedish Research Council
This sponsor has funded 2 studies across 6 countries.
| EU PAS ID | Status | RMP requirement | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|---|
| 3847 | Ongoing | Unspecified | The European Drug-induced Agranulocytosis Consortium Study (The EuDAC Study) | Yes | No |
| 36621 | Finalised | Not included in RMP | Association between androgen deprivation therapy and excess mortality after covid-19 in patients with prostate cancer | No | Yes |
PAS by Risk Management Plan (RMP) requirement
Swedish Research Council
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Swedish Research Council
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Swedish Research Council
6 Study countries specified are the following:
- France
- Germany
- Netherlands
- Spain
- Sweden
- United Kingdom